{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000141","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.233686+00:00","generated_at":"2026-05-31T14:53:18.574150+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MacroGenics discontinues vobra duo dosing in TAMARACK Phase 2 mCRPC study on IDMC safety recommendation","bullets":["IDMC recommended stopping dosing for remaining participants; most had received 8-12 cycles.","Emerging adverse events from prolonged exposure cited; participants continue safety and survival follow-up.","Primary endpoint 6-month rPFS data to be presented at ESMO Congress September 2024.","Company will not hold Q2 2024 earnings call; financial results release expected August 6.","Investor conference call planned after ESMO presentation to discuss next steps for vobra duo."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000141","json":"https://secwatch.observer/filing/0001125345-24-000141.json","markdown":"https://secwatch.observer/filing/0001125345-24-000141.md","text":"https://secwatch.observer/filing/0001125345-24-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000141/0001125345-24-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000141/mgnx-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:53:18.574150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}